{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:24:08Z","timestamp":1790166248243,"version":"4.1.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Biologic and clinical observations suggest that combining imatinib with IFN-\u03b1 may improve treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed chronic-phase CML patients with a low or intermediate Sokal risk score and in imatinib-induced complete hematologic remission either to receive a combination of pegylated IFN-\u03b12b (Peg\u2013IFN-\u03b12b) 50 \u03bcg weekly and imatinib 400 mg daily (n = 56) or to receive imatinib 400 mg daily monotherapy (n = 56). The primary endpoint was the major molecular response (MMR) rate at 12 months after randomization. In both arms, 4 patients (7%) discontinued imatinib treatment (1 because of blastic transformation in imatinib arm). In addition, in the combination arm, 34 patients (61%) discontinued Peg\u2013IFN-\u03b12b, most because of toxicity. The MMR rate at 12 months was significantly higher in the imatinib plus Peg\u2013IFN-\u03b12b arm (82%) compared with the imatinib monotherapy arm (54%; intention-to-treat, P = .002). The MMR rate increased with the duration of Peg\u2013IFN-\u03b12b treatment (&lt; 12-week MMR rate 67%, &gt; 12-week MMR rate 91%). Thus, the addition of even relatively short periods of Peg\u2013IFN-\u03b12b to imatinib markedly increased the MMR rate at 12 months of therapy. Lower doses of Peg\u2013IFN-\u03b12b may enhance tolerability while retaining efficacy and could be considered in future protocols with curative intent.<\/jats:p>","DOI":"10.1182\/blood-2011-02-336685","type":"journal-article","created":{"date-parts":[[2011,6,18]],"date-time":"2011-06-18T04:24:28Z","timestamp":1308371068000},"page":"3228-3235","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":166,"title":["Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia"],"prefix":"10.1182","volume":"118","author":[{"given":"Bengt","family":"Simonsson","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, University of Uppsala and Department of Hematology, University Hospital, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[{"name":"Department of Medicine, Oslo University Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Markev\u00e4rn","sequence":"additional","affiliation":[{"name":"Department of Radiation Sciences, University of Ume\u00e5 and Division of Hematology, Department of Oncology, University Hospital, Ume\u00e5, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Remes","sequence":"additional","affiliation":[{"name":"Hematology Unit, Turku University Hospital, Turku, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Stentoft","sequence":"additional","affiliation":[{"name":"Hematology Unit, University Hospital, Aarhus, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Almqvist","sequence":"additional","affiliation":[{"name":"Hematology Unit, Vaasa Central Hospital, Vaasa, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Bj\u00f6reman","sequence":"additional","affiliation":[{"name":"Hematology Unit, University Hospital, \u00d6rebro, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Flogeg\u00e5rd","sequence":"additional","affiliation":[{"name":"Hematology Unit, Falun Central Hospital, Falun, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perttu","family":"Koskenvesa","sequence":"additional","affiliation":[{"name":"Hematology Research Unit Helsinki and Division of Hematology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Lindblom","sequence":"additional","affiliation":[{"name":"Hematology Unit, Malm\u00f6 University Hospital, Malm\u00f6, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Malm","sequence":"additional","affiliation":[{"name":"Hematology Unit, Link\u00f6ping University Hospital, Link\u00f6ping, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[{"name":"Hematology Research Unit Helsinki and Division of Hematology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Myhr-Eriksson","sequence":"additional","affiliation":[{"name":"Hematology Unit, Lule\u00e5 Central Hospital, Lule\u00e5, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotta","family":"Ohm","sequence":"additional","affiliation":[{"name":"Karolinska Hospital, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"R\u00e4s\u00e4nen","sequence":"additional","affiliation":[{"name":"Hematology Unit, Kymenlaakso Central Hospital, Kotka, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjatta","family":"Sinisalo","sequence":"additional","affiliation":[{"name":"Hematology Unit, Tampere University Hospital, Tampere, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Sj\u00e4lander","sequence":"additional","affiliation":[{"name":"Hematology Unit, Sundsvall Central Hospital, Sundsvall, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Str\u00f6mberg","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Uppsala and Department of Hematology, University Hospital, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Weiss","family":"Bjerrum","sequence":"additional","affiliation":[{"name":"Hematology Unit, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Ehrencrona","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala and Department of Clinical Genetics, Lund University, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Gruber","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Troms\u00f8, Troms\u00f8, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veli","family":"Kairisto","sequence":"additional","affiliation":[{"name":"Tykslab, Turku University Central Hospital, Turku, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Olsson","sequence":"additional","affiliation":[{"name":"Regional Oncological Center, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Sandin","sequence":"additional","affiliation":[{"name":"Regional Oncological Center, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[{"name":"Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Med Center, Tel-Hashomer, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan Lanng","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Hematology Unit, University Hospital, Aarhus, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hjorth-Hansen","sequence":"additional","affiliation":[{"name":"Department of Hematology, St Olavs Hospital Trondheim, Trondheim, Norway; and"},{"name":"Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[{"name":"Hematology Research Unit Helsinki and Division of Hematology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Nordic CML Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"35","key":"2019111807280384200_B1","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111807280384200_B2","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111807280384200_B3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1532\/IJH97.04013","article-title":"Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia.","volume":"79","author":"Tauchi","year":"2004","journal-title":"Int J Hematol"},{"issue":"5","key":"2019111807280384200_B4","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood.V99.5.1527","article-title":"A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.","volume":"99","author":"Baccarani","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2019111807280384200_B5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia: French Chronic Myeloid Leukemia Study Group.","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111807280384200_B6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3109\/10428190009089437","article-title":"A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study.","volume":"37","author":"Giles","year":"2000","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111807280384200_B7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0145-2126(02)00223-0","article-title":"A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).","volume":"27","author":"Kuhr","year":"2003","journal-title":"Leuk Res"},{"issue":"7","key":"2019111807280384200_B8","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","article-title":"In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.","volume":"97","author":"Kano","year":"2001","journal-title":"Blood"},{"issue":"5","key":"2019111807280384200_B9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2000.110973","article-title":"Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.","volume":"68","author":"Glue","year":"2000","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2019111807280384200_B10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/10428190601175393","article-title":"Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia.","volume":"48","author":"Lipton","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111807280384200_B11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.leu.2403217","article-title":"Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.","volume":"18","author":"Michallet","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"2019111807280384200_B12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.bloodjournal634789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia.","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"20","key":"2019111807280384200_B13","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111807280384200_B14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2019111807280384200_B15","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe.","volume":"23","author":"Muller","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"2019111807280384200_B16","first-page":"4559","article-title":"Nordic CML Study Group Quality and Standardization Rounds for Quantitative RT-PCR of BCR-ABL to Facilitate Reporting on the International Scale.","volume":"110","author":"Bostrom","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"26","key":"2019111807280384200_B17","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111807280384200_B18","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3324\/haematol.12265","article-title":"Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"issue":"21","key":"2019111807280384200_B19","first-page":"357","article-title":"Superior CMR-rates with tolerability-adapted imatinib 800 mg vs. 400 mg vs. 400 Mg + IFN in CML: the Randomized German CML-Study IV.","volume":"116","author":"Hehlmann","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"6","key":"2019111807280384200_B20","first-page":"441","article-title":"Molecular responses of the Spirit phase III trial of the French CML Group comparing imatinib 400 mg to higher dose imatinib or combination with interferon or cytarabine for the treatment of newly diagnosed chronic phase (cp) chronic myeloid leukaemia (CML) patients [abstract].","volume":"94","author":"Rousselot","year":"2009","journal-title":"Haematologica"},{"issue":"11","key":"2019111807280384200_B21","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood.V97.11.3491","article-title":"Expression of interferon consensus sequence binding protein induces potent immunity against BCR\/ABL-induced leukemia.","volume":"97","author":"Deng","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2019111807280384200_B22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.leu.2400965","article-title":"Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia.","volume":"12","author":"Cortes","year":"1998","journal-title":"Leukemia"},{"issue":"2","key":"2019111807280384200_B23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/sj.leu.2400919","article-title":"Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon.","volume":"12","author":"Oka","year":"1998","journal-title":"Leukemia"},{"issue":"8","key":"2019111807280384200_B24","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111807280384200_B25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","article-title":"Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.","volume":"101","author":"Burchert","year":"2003","journal-title":"Blood"},{"issue":"9","key":"2019111807280384200_B26","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"issue":"3","key":"2019111807280384200_B27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/BF03006921","article-title":"Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia.","volume":"86","author":"Nakayama","year":"2007","journal-title":"Int J Hematol"},{"issue":"11","key":"2019111807280384200_B28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"24","key":"2019111807280384200_B29","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111807280384200_B30","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/12\/3228\/1340761\/zh803811003228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/12\/3228\/1340761\/zh803811003228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:35:41Z","timestamp":1574080541000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/12\/3228\/28802\/Combination-of-pegylated-IFN%CE%B12b-with-imatinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,22]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-02-336685","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,22]]}}}